Structure-based Drug Design, ADME and Molecular Docking analyses of anti-viral agents against SARS-CoV-2 virus, Zika virus and Hepatitis C virus
Abstract
Computer-aided drug design has been taking an increasing role in the field of modern drug discovery. These in silico computational methods are cost-effective, reduce the use of animal models in pharmacological research, and can be used to study pathogenic organisms without the need for any facilities. Based on the structure of known anti-viral agents, a total of 812 ligands have been designed. All ligands were screened for drug-likeness based on Lipinski rule of five. A database of ligands was constructed and in silico docking analyses were performed using MOE 2015.10 program against three selected viruses, viz., Zika virus, Hepatitis C virus and SARS-CoV-2 virus. Ligand 93 (-8.4469 kcal/mol) and ligand 123 (-8.3609 kcal/mol) were identified to be having higher docking scores as compared to the native ligand 6T8 (-8.2839 kcal/mol) and could be considered potential candidates for further studies in anti-viral drugs against Zika virus. Ligands 153 (-10.3108 kcal/mol), 63 (-9.9968 kcal/mol), 621 (-9.8700 kcal/mol), 31 (-9.5001 kcal/mol) and 779 (-9.3874 kcal/com) were identified as the top five binding ligands, and have docking scores much higher than the reference native ligand K4J (-8.9037 kcal/com). All these ligands can be potent candidates for anti-viral research against Hepatitis C virus. Ligand 798 (-8.0957 kcal/com) and ligand 63 (-8.0778 kcal/com) have higher docking scores as compared to the reference native ligand X77 (-8.0689 kcal/mol), they also interact with the catalytic dyad at the active site of the target protein and can be considered as possible candidates for studies in anti-viral drugs against SARS-CoV-2.
Keywords: Computer-aided drug design, ADME, Molecular Docking analyses, anti-viral agents, Sars-CoV-2 virus, Zika virus, Hepatitis C virus
Keywords:
Computer-aided drug design, ADME, Molecular Docking analyses, anti-viral agents, Sars-CoV-2 virus, Zika virus, Hepatitis C virusDOI
https://doi.org/10.22270/jddt.v13i7.5909References
Westaway EG, Brinton MA, Gaidamovich Ya, et al. Flaviviridae. Intervirology. 1985; 24(4):183-192. https://doi.org/10.1159/000149642
Chang C, Ortiz K, Ansari A, Gershwin ME. The Zika outbreak of the 21st century. J Autoimmun. 2016; 68:1-13. https://doi.org/10.1016/j.jaut.2016.02.006
Rawal G, Yadav S, Kumar R. Zika virus: An overview. J Family Med Prim Care. 2016; 5(3):523. https://doi.org/10.4103/2249-4863.197256
Alam A, Imam N, farooqui A, Ali S, Malik MdZ, Ishrat R. Recent trends in ZikV research: A step away from cure. Biomedicine & Pharmacotherapy. 2017; 91:1152-1159. https://doi.org/10.1016/j.biopha.2017.05.045
Lee J, Shin O. Advances in Zika Virus–Host Cell Interaction: Current Knowledge and Future Perspectives. Int J Mol Sci. 2019; 20(5):1101. https://doi.org/10.3390/ijms20051101
Valente AP, Moraes AH. Zika virus proteins at an atomic scale: how does structural biology help us to understand and develop vaccines and drugs against Zika virus infection? Journal of Venomous Animals and Toxins including Tropical Diseases. 2019; 25. https://doi.org/10.1590/1678-9199-jvatitd-2019-0013
Simmonds P. The Origin of Hepatitis C Virus. In: Hepatitis C Virus: From Molecular Virology to antiviral therapy; 2013:1-15. https://doi.org/10.1007/978-3-642-27340-7_1
Forni D, Cagliani R, Pontremoli C, et al. Evolutionary Analysis Provides Insight Into the Origin and Adaptation of HCV. Front Microbiol. 2018; 9. https://doi.org/10.3389/fmicb.2018.00854
Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015; 61(1):77-87. https://doi.org/10.1002/hep.27259
Offersgaard A, Bukh J, Gottwein JM. Toward a vaccine against hepatitis C virus. Science (1979). 2023; 380(6640):37-38. https://doi.org/10.1126/science.adf2226
Müge Toygar Deniz, Sıla Akhan. Hepatitis C Virus Structure and Diagnostic Methods. In: Xingshun Qi, Li Yang, eds. Hepatitis C. ; 2023.
Chong PY, Shotwell JB, Miller J, et al. Design of N-Benzoxaborole Benzofuran GSK8175 Optimization of Human Pharmacokinetics Inspired by Metabolites of a Failed Clinical HCV Inhibitor. J Med Chem. 2019; 62(7):3254-3267. https://doi.org/10.1021/acs.jmedchem.8b01719
Holmes EC, Goldstein SA, Rasmussen AL, et al. The origins of SARS-CoV-2: A critical review. Cell. 2021; 184(19):4848-4856. https://doi.org/10.1016/j.cell.2021.08.017
Yousefi B, Eslami M. Genetic and structure of novel coronavirus COVID-19 and molecular mechanisms in the pathogenicity of coronaviruses. Reviews in Medical Microbiology. 2022; 33(1):e180-e188. https://doi.org/10.1097/MRM.0000000000000265
Hillary VE, Ceasar SA. An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. Heliyon. 2023; 9(3):e13952. https://doi.org/10.1016/j.heliyon.2023.e13952
Mengist HM, Dilnessa T, Jin T. Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease. Front Chem. 2021; 9. https://doi.org/10.3389/fchem.2021.622898
Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. Journal of the Chinese Medical Association. 2020; 83(3):217-220. https://doi.org/10.1097/JCMA.0000000000000270
Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H. The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. Front Immunol. 2020; 11. https://doi.org/10.3389/fimmu.2020.576622
Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021; 19(7):409-424. https://doi.org/10.1038/s41579-021-00573-0
Sarkar A, Mandal K. Repurposing an Antiviral Drug against SARS‐CoV‐2 Main Protease. Angewandte Chemie International Edition. 2021; 60(44):23492-23494. https://doi.org/10.1002/anie.202107481
Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen KY. Coronaviruses — drug discovery and therapeutic options. Nat Rev Drug Discov. 2016; 15(5):327-347. https://doi.org/10.1038/nrd.2015.37
Ullrich S, Nitsche C. The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett. 2020; 30(17):127377. https://doi.org/10.1016/j.bmcl.2020.127377
Ullrich S, Ekanayake KB, Otting G, Nitsche C. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir. Bioorg Med Chem Lett. 2022; 62:128629. https://doi.org/10.1016/j.bmcl.2022.128629
Nguyen DD, Gao K, Chen J, Wang R, Wei GW. Unveiling the molecular mechanism of SARS-CoV-2 main protease inhibition from 137 crystal structures using algebraic topology and deep learning. Chem Sci. 2020; 11(44):12036-12046. https://doi.org/10.1039/D0SC04641H
Lei J, Hansen G, Nitsche C, Klein CD, Zhang L, Hilgenfeld R. Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor. Science (1979). 2016; 353(6298):503-505. https://doi.org/10.1126/science.aag2419
Molecular Operating Environment. Published online 2022.
Desideri N, Fioravanti R, Proietti Monaco L, et al. Design, Synthesis, Antiviral Evaluation, and SAR Studies of New 1-(Phenylsulfonyl)-1H-Pyrazol−4-yl-Methylaniline Derivatives. Front Chem. 2019; 7. https://doi.org/10.3389/fchem.2019.00214
Saudi M, Zmurko J, Kaptein S, Rozenski J, Neyts J, Van Aerschot A. Synthesis and evaluation of imidazole-4,5- and pyrazine-2,3-dicarboxamides targeting dengue and yellow fever virus. Eur J Med Chem. 2014; 87:529-539. https://doi.org/10.1016/j.ejmech.2014.09.062
M.A. Eldebss T, M. Farag A, M. Abdulla M, K. Arafa R. Novel Benzo[d]imidazole-based Heterocycles as Broad Spectrum Anti-viral Agents: Design, Synthesis and Exploration of Molecular Basis of Action. Mini-Reviews in Medicinal Chemistry. 2015; 16(1):67-83. https://doi.org/10.2174/138955751601151029115533
Cousins KR. ChemDraw Ultra 9.0. CambridgeSoft, 100 CambridgePark Drive, Cambridge, MA 02140. www. cambridgesoft.com. See Web site for pricing options. J Am Chem Soc. 2005; 127(11):4115-4116. https://doi.org/10.1021/ja0410237
O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminform. 2011; 3(1):33. https://doi.org/10.1186/1758-2946-3-33
Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004; 1(4):337-341. https://doi.org/10.1016/j.ddtec.2004.11.007
Jayaram B, Singh T, Mukherjee G, Mathur A, Shekhar S, Shekhar V. Sanjeevini: a freely accessible web-server for target directed lead molecule discovery. BMC Bioinformatics. 2012; 13(S17):S7. https://doi.org/10.1186/1471-2105-13-S17-S7
Published
Abstract Display: 613 
PDF Downloads: 575 PDF Downloads: 60 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.